You’ve probably heard the term “hair cloning” thrown around in articles, ads, and online forums. It sounds futuristic, like scientists could photocopy your hair follicles and give you a full head of hair overnight.

That’s not quite how it works. What researchers are actually developing is called hair multiplication, and understanding the difference will help you spot real progress and avoid falling for marketing hype.

What Is Hair Multiplication?

Hair multiplication is a process where doctors take a small sample of your hair follicles, grow certain cells from them in a laboratory, and then inject those cells back into thinning areas of your scalp.

Here’s the important part: those cells don’t create brand-new follicles from scratch. Instead, they find your existing weakened follicles and help them recover. The terminology matters because it shapes what you should realistically expect. Think of it like giving a struggling plant fertilizer rather than planting a new seed; you’re working with what’s already there, not creating something entirely new.

Two Paths Researchers Are Exploring

Scientists have been working on two different approaches, and they work quite differently from each other.

Creating New Follicles (Neogenesis)

This approach has been achieved in laboratory settings, though not yet in human patients.

Before anyone treated patients, researchers mixed two types of cells, dermal cells and epidermal cells, and observed something remarkable: true new follicles formed in laboratory models. Using standardized testing methods, they watched tiny “islands” of hair emerge through a process where dermal cells found other dermal cells, epidermal cells found other epidermal cells, and then the dermal cells triggered follicle formation.

This revealed an essential recipe: both cell families need to be present for the magic to happen. It’s exciting science, but it hasn’t been successfully replicated in human patients yet.

Rescuing Existing Follicles (Regeneration)

This is what’s actually been tested in people.

When cultured cells are injected into human skin, something interesting occurs: the cells tend to home in on existing miniaturized follicles and repopulate them. The result is what researchers call chimeric follicles, which are follicles containing both your original cells and the newly injected cells. These chimeric follicles return toward a thicker, healthier state.

How do we know the injected cells actually integrated? Researchers used a clever tracking method: they injected male cells into female skin samples, and by looking for Y-chromosomes, they confirmed the injected cells had become part of the follicle structure.

The key takeaway is that in people, the effect is rescue and reinforcement, not mass follicle copying.

What Happened in Human Trials?

The process tested in clinical studies followed a straightforward path. First, doctors took a small donor biopsy from the back of the scalp. Then cells were expanded in a controlled laboratory facility over about two weeks. Finally, patients returned to have those cells injected into the scalp, with studies focusing on the crown area.

The results were encouraging: after a single injection, the treated area showed more visible terminal hairs at one year. That’s a durable improvement from just one session, not a treatment you need to repeat monthly or maintain indefinitely.

Why Both Cell Types Matter?

Many research groups favored using only dermal cells because they’re easier to grow in a laboratory setting. But there’s a problem with that approach: the epidermal cells (called keratinocytes) are crucial to the process, and they’re much harder to culture without losing their “hair identity.”

Programs that combine both dermal and epidermal cells credit that mix for stronger hair-forming performance in laboratory models and more meaningful follicle reinforcement in human systems. The synergy between these two cell types appears central to reliable hair biology; skip one, and you compromise the results.

Why Did Research Slow Down?

After initial safety studies showed the approach was safe and iterative work demonstrated real efficacy, researchers identified a new factor that increased what’s called trichogenicity, essentially, the cells’ hair-forming potential. They paused to optimize this discovery in additional studies.

Then the funding ran out, and the program went on hold.

This is a crucial point to understand: the pause reflected financing constraints, not failed biology. The science worked. The money didn’t follow. When you hear that a promising hair restoration technology stalled, it’s worth asking whether the problem was scientific failure or simply the harsh realities of research funding.

Where Things Stand Today

Excellent laboratories can often grow mouse hair robustly, but translating those results to human hair remains considerably harder. Some experimental systems create hybrid hairs that aren’t quite right. Clinical efforts using dermal-only approaches have shown limited success, with no market approvals so far.

Meanwhile, technology transfer and restart efforts are underway to recreate the prior human-focused systems that showed promise. Progress continues, but the species differences between mice and humans make translation non-trivial. What works beautifully in a mouse model doesn’t automatically work in people.

The field isn’t confined to one lab or one company, which is good news. Academic groups widely share methods and findings at international hair research meetings, and this circulation of knowledge speeds progress. Biotech teams collaborate less openly while products are in development, but they do publish results at key milestones.

What Would Treatment Actually Look Like?

If this technology reaches clinics in the near term, here’s the realistic scenario you’d likely experience:

You’d visit a specialized clinic where a doctor would take a small scalp biopsy. The laboratory would then separate and expand both dermal and epidermal cells over about two weeks. You’d return for injections into the thinning zone.

The goal isn’t to create hair where none exists. It’s to turn existing follicles back on and increase terminal hair counts over time. It’s a familiar clinic flow targeting miniaturized follicles you already have, not dramatically different from other injection-based treatments you might have encountered.

Early cell-based injectable treatments would likely cost somewhere between ongoing medications and surgical transplantation, though no fixed numbers exist yet. Costs will evolve as processes scale and mature. And yes, specialists will still be needed, cell injections can be performed by trained hair-loss clinicians, while surgeons would remain essential for any future implantation procedures.

What About Completely Bald Areas?

For scarred scalps or areas where follicles are completely gone, researchers are working on something more ambitious: growing actual follicle structures in the laboratory and implanting them like a transplant. This approach would be especially relevant for scarred areas or locations without existing follicles, situations where simply “turning on” dormant follicles won’t work because there’s nothing left to turn on.

Think of it as transplantation, except the follicles are manufactured rather than harvested from elsewhere on your scalp. This is the path toward coverage where follicles are completely absent. It’s further from clinical reality than the rescue approach, but it represents the next wave of possibility for people who can’t benefit from follicle reinforcement alone.

What Does This Mean For You?

Before getting excited about any treatment claiming to use this technology, consider a few questions to organize your thinking. 

• Do you have miniaturized follicles that could potentially be rescued, or is your scalp smooth and scarred?
• Are you comfortable with a biopsy, a two-week culture period, and an injection process?
• Can you target one area first, like the crown, rather than expecting a whole-scalp transformation?
• And crucially, will you commit to a one-year follow-up to properly assess results?

The approach studied in trials was area-focused and required meaningful follow-up time to evaluate. Anyone promising instant or whole-head results from current technology isn’t describing what’s actually been demonstrated.

The Bottom Line

Stop chasing the word “cloning.” It implies one-for-one follicle duplication, and that’s not what human results have shown.

Focus instead on multiplication outcomes: repopulation of existing miniaturized follicles and measurable terminal-hair gains after a single injection in a defined area. When you evaluate claims by the mechanism actually observed, rather than the buzzwords used to describe it, you’ll make much better decisions about your options.

The science is real. The challenge now is funding, optimization, and getting proven approaches to market. Understanding what’s genuinely possible will help you stay informed without getting swept up in premature excitement.